-
Consensus Rating
HoldBased on 28 Analyst Ratings
-
Consensus Price Target
$11.3348.1% Upside
Adverum Biotechnologies, Inc. Frequently Asked Questions
-
What analysts cover Adverum Biotechnologies, Inc.?
Adverum Biotechnologies, Inc. has been rated by research analysts at Mizuho Securities, RBC Capital, Chardan Capital in the past 90 days.